Cell-free protein synthesis (CFPS) systems are a powerful platform with immense potential in fundamental research, biotechnology, and synthetic biology. Conventional prokaryotic CFPS systems, ...

Forward Looking Statements: This new release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of ...

Cancer vaccines' efficacy can be tested on an organ-on-a-chip platform that replicates age-related immune decline.

Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Learn how Logic-gated DARPins work to activate T cells selectively in solid tumours, enhancing therapeutic outcomes.

Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus ...

Rondo Therapeutics begins patient dosing in phase 1/1b trial of RNDO-564 in adults with r/r locally advanced or metastatic urothelial carcinoma: Hayward, California Saturday, Dece ...

Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates ...

Immunosenescence , the natural decline of the immune system with age, significantly reduces the effectiveness of cancer ...

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation ...